EP0393707A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Bioactive compounds associated with liposomes and their use in pharmaceutical preparations
Assignee: Otsuka Pharmaceutical Co Ltd
•
Filing: 1990-04-20
•
Granted: —
•
Expires: 2010-04-20
Abstract
Abstract A method of treating a patient with bioactive agents comprises providing aggregates of bioactive agents in association with liposomes, wherein the aggregates comprise liposomes having outer surfaces, and bioactive agents, wherein the bioactive agent is associated with the outer surfaces of the liposomes such that biological activity is not substantially diminished when the aggregates are administered in a pharmaceutically effective amount to a patient, and administering the aggregates to the patient. Preferred bioactive agents are TGF-β and M-CSF. A preferred method comprises aggregates of negatively-charged liposomes and TGF-β, having a net positive charge. In addition, a composition of matter comprises aggregates of TGF-β in association with liposomes. A pharmaceutical composition comprises the aggregates of TGF-β in association with liposomes in conjunction with pharmaceutically-acceptable carriers. A preferred method comprises aggregates of positively-charged liposomes and M-CSF, having a net negative charge. In addition, a composition of matter comprises aggregates of M-CSF in association with liposomes. A pharmaceutical composition comprises the aggregates of M-CSF in association with liposomes in conjunction with pharmaceutically-acceptable carriers.
Inventors
- 👤 Gideon Strassmann
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-06 10:46
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/10; A61K9/127; A61K9/1271
Claims Analysis
Total Claims: 57
Claim 1
Independent Claim
80 words
A method of treating a patient with bioactive agents, comprising: (a) providing aggregates of bioactive agents in association with liposomes, wherein the aggregates comprise i. liposomes having outer surfaces; and ii. bioactive agents; wherein the bioactive agent is associated with the outer surfaces of the liposome such that the biological activity of the bioactive agent is not substantially diminished when the aggregates are administered in a pharmaceutically effective amount to a patient, and (b) administering the aggregates to the patients.
Claim 2
Independent Claim
80 words
A method of treating a patient with bioactive agents, comprising: (a) providing aggregates of bioactive agents in association with liposomes, wherein the aggregates comprise i. liposomes having outer surfaces; and ii. bioactive agents; wherein the bioactive agent is associated with the outer surfaces of the liposome such that the biological activity of the bioactive agent is not substantially diminished when the aggregates are administered in a pharmaceutically effective amount to a patient, and (b) administering the aggregates to the patients.
Claim 3
Dependent Claim
19 words
The method of claim 1, wherein the bioactive agents are selected from the group consisting of TGF-β and M-CSF.
Claim 4
Dependent Claim
24 words
The method of claim 1, wherein the liposomes are selected from the group consisting of small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
Claim 5
Dependent Claim
12 words
The method of claim 3, wherein the liposomes are small unilamellar vesicles.
Claim 6
Dependent Claim
18 words
The method of claim 4, wherein the small unilamellar vesicles are comprised of phosphatidyl choline and phosphatidyl serine.
Claim 7
Dependent Claim
19 words
The method of claim 5, wherein the phosphatidyl choline and phosphatidyl serine are in a molar ratio of 1:1.
Claim 8
Dependent Claim
17 words
The method of claim 4 wherein the small unilamellar vesicles are comprised on phosphatidyl choline and stearylamine.
Claim 9
Dependent Claim
71 words
A composition of matter, comprising: aggregates of a bioactive agent in association with liposomes, wherein the aggregates comprise: (a) a multiplicity of liposomes having outer surfaces; and (b) a multiplicity of bioactive agents; wherein the bioactive agent is associated with the outer surfaces of the liposome such that biological activity of the bioactive agent is not substantially diminished when the aggregates are administered in a pharmaceutically effective amount to a patient.
Claim 10
Dependent Claim
71 words
A composition of matter, comprising: aggregates of a bioactive agent in association with liposomes, wherein the aggregates comprise: (a) a multiplicity of liposomes having outer surfaces; and (b) a multiplicity of bioactive agents; wherein the bioactive agent is associated with the outer surfaces of the liposome such that biological activity of the bioactive agent is not substantially diminished when the aggregates are administered in a pharmaceutically effective amount to a patient.
Claim 11
Dependent Claim
19 words
The composition of claim 8, wherein the bioactive agent is selected from a group consising of TGF-β and M-CSF.
Claim 12
Dependent Claim
23 words
The composition of claim 8, wherein the liposomes are selected from a group comprising small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
Claim 13
Dependent Claim
12 words
The composition of claim 10, wherein the liposomes are small unilamellar vesicles.
Claim 14
Dependent Claim
18 words
The composition of claim 11, wherein the small unilamellar vesicles are comprised of phosphatidyl choline and phosphatidyl serine.
Claim 15
Dependent Claim
19 words
The composition of claim 12, wherein the phosphatidyl choline and phosphatidyl serine are in a molar ratio of 1:1.
Claim 16
Dependent Claim
17 words
The composition of claim 11, wherein the small unilamellar vesicles are comprised of phosphatidyl choline and stearylamine.
Claim 17
Dependent Claim
21 words
A pharmaceutical composition comprising: (a) a pharmaceutically effective amount of the composition of claim 8, and (b) a pharmaceutically acceptable carrier.
Claim 18
Dependent Claim
21 words
A pharmaceutical composition comprising: (a) a pharmaceutically effective amount of the composition of claim 9, and (b) a pharmaceutically acceptable carrier.
Claim 19
Dependent Claim
21 words
A pharmaceutical composition comprising: (a) a pharmaceutically effective amount of the composition of claim 10, and (b) a pharmaceutically acceptable carrier.
Claim 20
Dependent Claim
21 words
A pharmaceutical composition comprising: (a) a pharmaceutically effective amount of the composition of claim 11, and (b) a pharmaceutically acceptable carrier.
Claim 21
Dependent Claim
21 words
A pharmaceutical composition comprising: (a) a pharmaceutically effective amount of the composition of claim 12, and (b) a pharmaceutically acceptable carrier.
Claim 22
Dependent Claim
21 words
A pharmaceutical composition comprising: (a) a pharmaceutically effective amount of the composition of claim 13, and (b) a pharmaceutically acceptable carrier.
Claim 23
Dependent Claim
21 words
A pharmaceutical composition comprising: (a) a pharmaceutically effective amount of the composition of claim 14, and (b) a pharmaceutically acceptable carrier.
Claim 24
Independent Claim
97 words
A method of treating a patient with a bioactive agent, comprising: (a) providing aggregates of bioactive agents in association with liposomes, wherein the aggregates comprise: i. charged liposomes having outer surfaces; and ii. a bioactive agent, having a net charge that is the complement of the charge on the liposomes; wherein the bioactive agent is associated with the outer surfaces of the liposome such that the biological activity of the bioactive agent is not substantially diminished when the aggregates are administered in a pharmaceutically effective amount to a patient, and (b) administering the aggregates to the patients.
Claim 25
Independent Claim
97 words
A method of treating a patient with a bioactive agent, comprising: (a) providing aggregates of bioactive agents in association with liposomes, wherein the aggregates comprise: i. charged liposomes having outer surfaces; and ii. a bioactive agent, having a net charge that is the complement of the charge on the liposomes; wherein the bioactive agent is associated with the outer surfaces of the liposome such that the biological activity of the bioactive agent is not substantially diminished when the aggregates are administered in a pharmaceutically effective amount to a patient, and (b) administering the aggregates to the patients.
Claim 26
Dependent Claim
22 words
The method of claim 22, wherein the liposomes bear a net negative charge and the bioactive compound bears a net positive charge.
Claim 27
Dependent Claim
11 words
The method of claim 23, wherein the bioactive compound is TGF-β.
Claim 28
Dependent Claim
22 words
The method of claim 22, wherein the liposomes bear a net positive charge and the bioactive agent bears a net negative charge.
Claim 29
Dependent Claim
11 words
The method of claim 25, wherein the bioactive agent is M-CSF.
Claim 30
Dependent Claim
25 words
The method of claim 22, wherein the charged liposomes are selected from the group consisting of small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
Claim 31
Dependent Claim
12 words
The method of claim 27, wherein the liposomes are small unilamellar vesicles.
Claim 32
Dependent Claim
18 words
The method of claim 28, wherein the small unilamellar vesicles are comprised of phosphatidyl choline and phosphatidyl serine.
Claim 33
Dependent Claim
19 words
The method of claim 29, wherein the phosphatidyl choline and phosphatidyl serine are in a molar ratio of 1:1.
Claim 34
Dependent Claim
17 words
The method of claim 28, wherein the small unilamellar vesicles are comprised of phosphatidyl choline and stearylamine.
Claim 35
Dependent Claim
84 words
A composition of matter, comprising: aggregates of bioactive agents in association with liposomes, wherein the aggregates comprise (a) a multiplicity of charged liposomes having outer surfaces; and (b) a multiplicity of bioactive agents, having a charge that is the complement to the charge on the liposomes; wherein the bioactive agent is associated with the outer surfaces of the liposome such that biological activity of the bioactive agent is not substantially diminished when the aggregates are administered in a pharmaceutically effective amount to a patient.
Claim 36
Dependent Claim
84 words
A composition of matter, comprising: aggregates of bioactive agents in association with liposomes, wherein the aggregates comprise (a) a multiplicity of charged liposomes having outer surfaces; and (b) a multiplicity of bioactive agents, having a charge that is the complement to the charge on the liposomes; wherein the bioactive agent is associated with the outer surfaces of the liposome such that biological activity of the bioactive agent is not substantially diminished when the aggregates are administered in a pharmaceutically effective amount to a patient.
Claim 37
Dependent Claim
20 words
The composition of matter of claim 32, wherein the liposome is negatively charged and the bioactive agent is positively charged.
Claim 38
Dependent Claim
13 words
The composition of matter of claim 33, wherein the bioactive agent is TGF-β.
Claim 39
Dependent Claim
20 words
The composition of matter of claim 32, wherein the liposomes are positively charged and the bioactive agent is negatively charged.
Claim 40
Dependent Claim
13 words
The composition of matter of claim 35, wherein the bioactive agent is M-CSF.
Claim 41
Dependent Claim
27 words
The composition of matter of claim 32, wherein the charged liposomes are selected from the group consisting of small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
Claim 42
Dependent Claim
14 words
The composition of matter of claim 37, wherein the liposomes are small unilamellar vesicles.
Claim 43
Dependent Claim
20 words
The composition of matter of claim 38, wherein the small unilamellar vesicles are comprised of phosphatidyl choline and phosphatidyl serine.
Claim 44
Dependent Claim
21 words
The composition of matter of claim 39, wherein the phosphatidyl choline and phosphatidyl serine are in a molar ratio of 1:1.
Claim 45
Dependent Claim
19 words
The composition of matter of claim 38, wherein the small unilamellar vesicles are comprised of phosphatidyl choline and stearylamine.
Claim 46
Dependent Claim
21 words
A pharmaceutical composition comprising: (a) a pharmaceutically effective amount of the composition of claim 32, and (b) a pharmaceutically acceptable carrier.
Claim 47
Dependent Claim
21 words
A pharmaceutical composition comprising: (a) a pharmaceutically effective amount of the composition of claim 33, and (b) a pharmaceutically acceptable carrier.
Claim 48
Dependent Claim
21 words
A pharmaceutical composition comprising: (a) a pharmaceutically effective amount of the composition of claim 34, and (b) a pharmaceutically acceptable carrier.
Claim 49
Dependent Claim
21 words
A pharmaceutical composition comprising: (a) a pharmaceutically effective amount of the composition of claim 35, and (b) a pharmaceutically acceptable carrier.
Claim 50
Dependent Claim
21 words
A pharmaceutical composition comprising: (a) a pharmaceutically effective amount of the composition of claim 36, and (b) a pharmaceutically acceptable carrier.
Claim 51
Dependent Claim
21 words
A pharmaceutical composition comprising: (a) a pharmaceutically effective amount of the composition of claim 37, and (b) a pharmaceutically acceptable carrier.
Claim 52
Dependent Claim
21 words
A pharmaceutical composition comprising: (a) a pharmaceutically effective amount of the composition of claim 38, and (b) a pharmaceutically acceptable carrier.
Claim 53
Dependent Claim
21 words
A pharmaceutical composition comprising: (a) a pharmaceutically effective amount of the composition of claim 39, and (b) a pharmaceutically acceptable carrier.
Claim 54
Dependent Claim
21 words
A pharmaceutical composition comprising: (a) a pharmaceutically effective amount of the composition of claim 40, and (b) a pharmaceutically acceptable carrier.
Claim 55
Dependent Claim
21 words
A pharmaceutical composition comprising: (a) a pharmaceutically effective amount of the composition of claim 41, and (b) a pharmaceutically acceptable carrier.
Claim 56
Dependent Claim
24 words
The use of an aggregate comprising a bioactive agent in association with the outer surface of a liposome for the manufacture of a pharmaceutical.
Claim 57
Dependent Claim
24 words
The use of an aggregate comprising a bioactive agent in association with the outer surface of a liposome for the manufacture of a pharmaceutical.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.